recent host meet investor manag
compani corpor headquart pleasanton california
meet manag call coopervis organ
growth busi clear compani would disappoint growth
closer market compani see grow rang
includ recent think reason rang
coopervis next year note compani suggest
see potenti opportun deliv double-digit coopervis organ
growth result upcom quarter led key account initi
hear alcon expect launch mass market daili silicon
hydrogel len push back late summer
month away hear back fda regard regulatori
path misight len myopia control compani said
probabl take year misight contribut meaning overal
revenu think time could sooner need submit data
intern misight trial strong four-year follow-up data
highlight press releas last week
think interest expens like level
compani anticip lighter year acquisit activ
focu debt repay potenti share repurchas given
feedback rais adjust ep estim
reflect lower interest expens assumpt
manag think tax rate like come
rate indic fiscal earn call tax depart feel
comfort model tax rate point note bp
decreas coo adjust tax rate estim would add
adjust ep forecast
overal encourag coopervis opportun key account
initi compani made necessari invest distribut
packag manufactur sale forc ideal product clariti
penetr segment invest intermediate-term
opportun misight myopia control think path toward sustain
above-market organ growth coopervis clearer investor
currenc chang tax present headwind remain
confid long-term growth opportun rate remain
import pleas read disclosur disclaim page report
total debt total asset
recent host meet investor al white coo ceo duncan coo vice-president investor
relat administr compani corpor headquart pleasanton california key
takeaway meet highlight
meet manag call coopervis organ growth busi
clear compani would disappoint growth closer market compani see
grow rang includ recent think reason rang
coopervis next year note compani suggest see potenti opportun
deliv double-digit coopervis organ growth result upcom quarter
manag shorter-term optim regard coopervis outlook appear driven
earli success effort win increment busi key account includ larger retail
buy group influenc optometrist purchas note coopervis
increas emphasi key account roughli year ago follow compani invest
manufactur distribut sale forc support initi compani begun
discuss program recent investor start impact result gener
coopervis exist relationship vast major key account typic
biofin monthli silicon hydrogel len famili key account program coopervis primarili
focus expand sale daili lens coopervis market share versu
overal busi larg retail buy group
view key account program way larg retail buy group potenti retain
contact len custom impact profit compani believ
custom offer custom label packag ship even custom len key account
prescrib len patient buy anywher howev prescrib custom len len
sold differ name ship monthli patient home believ may abl
impact sticki account
clear coo key account agreement exclus compani still work win
busi account compani hope abl drive strong growth key
account realloc advertis dollar support agreement secur
still earli key account initi benefit initi contract agreement
fulli seen compani fiscal result well like futur agreement help give
investor comfort coopervis abil maintain above-market growth note
coopervis market share win key account initi appear come primarili
alcon base report calendar result compani competitor
see alcon focu advertis dollar consum emphas brand name
similar respons coo market share win key account compani seen
increas discount alcon effort retain busi key account
hear alcon expect launch mass market daili silicon hydrogel len push
back late summer moreov compani think alcon
launch mass market daili silicon hydrogel len may roll back rebat daili
sphere could lead reduc rebat oasi myday respect lead
posit price environ
month away hear back fda regard regulatori path misight len
myopia control compani said probabl take year misight contribut
meaning overal revenu think time could sooner need submit data
intern misight trial strong four-year follow-up data highlight
press releas last week still think may abl submit five-year follow-up data next summer
potenti fda approv
ask sale forc hold back sell effort biofin energi period fiscal
end april could keep demand compani recent went back
sale forc said could sell bring addit manufactur line
view coopersurg organ growth busi driven mid-to-high-single-
digit growth fertil product busi mid-single-digit growth paragard
coopersurg expect rais price paragard similar fashion teva increas everi
three year rather implement annual price increas compani initi anticip given
last year price increas compani expect adjust paragard price year
think interest expens like level compani anticip
lighter year acquisit activ focu debt repay potenti share
repurchas given feedback rais adjust ep estim
reflect lower interest expens assumpt
manag think tax rate like come rate indic fiscal
earn call tax depart feel comfort model tax rate
point note bp decreas coo adjust tax rate estim would add
adjust ep forecast
expect duplic expens result distribut center invest
opportun leverag
anticip gross margin expans coopervis coopersurg compani also
suggest fiscal adjust gross margin coopersurg reason rang expect
divis shorter term
overal encourag coopervis opportun key account initi compani made
necessari invest distribut packag manufactur sale forc ideal product clariti
penetr segment invest intermediate-term opportun misight
myopia control think path toward sustain above-market organ growth coopervis
clearer investor currenc chang tax present headwind remain confid coo
long-term growth opportun rate remain buy
cooper compani inc annual incom statement analysi adjust northcoast research thousand except percent per share gross gross sg sg amort oper oper net interest interest incom incom incom incom tax minor net incom extra net margin extra extra net net wghd com share ep ep revenu growth adjust ep growth began exclud amort intang adjust ep follow sauflon acquisitionsourc compani report northcoast research estim disclosur
